Education
About Us
Working with TipRanks
Follow Us
NAYA Biosciences (NAYA)
NASDAQ:NAYA
NAYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $17.04
Previous CloseN/A
Volume42.13K
Average Volume (3M)3.09M
Market Cap
$1.20M
Enterprise ValueN/A
Total Cash (Recent Filing)$25.76K
Total Debt (Recent Filing)$342.61K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-30.54
Shares Outstanding666,058
10 Day Avg. Volume9,070,689
30 Day Avg. Volume3,094,701
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside11.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
NAYA Biosciences News
PremiumMarket News
3 Penny Stocks to Watch Now, 5/1/25
PremiumCompany Announcements
NAYA Biosciences Delays 2024 Yearly Report Filing
---
Bulls Say, Bears Say
Bulls Say
Analyst RatingsAnalyst's recommendation to upgrade shares to Buy reflects confidence in the company's revenue outlook related to its lead asset in cancer treatment.
Mergers And AcquisitionsThe merger of INVO Biosciences with NAYA Biosciences creates a strong focus on developing a portfolio of bifunctional antibodies.
Product DevelopmentThe bifunctional antibody NY-338 for multiple myeloma could potentially be a better option than current treatments, indicating a strong competitive position.
Bears Say
Capital RaisingRaising capital will likely take time in a particularly challenging market environment.
Regulatory IssuesThe company received a letter from Nasdaq indicating that the company failed to file its 10-K on a timely basis and as such, no longer satisfies listing rules.
Strategic ChallengesThe inability of the strategy to shift focus to oncology in general and bispecifics in particular is a disappointment, in our view.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.28% Mutual Funds
<0.01% Other Institutional Investors
78.60% Public Companies and
Individual Investors
NAYA FAQ
What was NAYA Biosciences’s price range in the past 12 months?
NAYA Biosciences lowest stock price was $1.38 and its highest was $17.04 in the past 12 months.
What is NAYA Biosciences’s market cap?
NAYA Biosciences’s market cap is $1.20M.
When is NAYA Biosciences’s upcoming earnings report date?
NAYA Biosciences’s upcoming earnings report date is May 19, 2025 which is in 14 days.
How were NAYA Biosciences’s earnings last quarter?
Currently, no data Available
Is NAYA Biosciences overvalued?
According to Wall Street analysts NAYA Biosciences’s price is currently Undervalued.
Does NAYA Biosciences pay dividends?
NAYA Biosciences does not currently pay dividends.
What is NAYA Biosciences’s EPS estimate?
NAYA Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NAYA Biosciences have?
NAYA Biosciences has 666,058 shares outstanding.
What happened to NAYA Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NAYA Biosciences?
Currently, no hedge funds are holding shares in NAYA
---
Company Description
NAYA Biosciences
INVO Bioscience is a medical device company providing devices and products for infertility diagnosis. Its flagship product is INVOcell, a reproductive technology that allows fertilization and early embryo development to take place within the woman’s body.
---
NAYA Stock 12 Month Forecast
Average Price Target
$2.00
▲(11.11% Upside)
Technical Analysis
Helius Medical Technologies
―
Catheter Precision
―
Bone Biologics
―
Bluejay Diagnostics
―
Tivic Health Systems
―
---